Ribociclib improves progression-free survival in advanced breast cancer

Bookmark and Share
Published: 8 Oct 2016
Views: 1732
Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US

Prof Hortobagyi speaks with ecancer at ESMO 2016 about results from the MONALEESA2 trial of ribociclib, a CDK4/6 inhibitor, in combination with letrozole.

Compared to letrozole alone, the addition of ribociclib improves progression free survival by 44% compared to placebo, which Prof Hortobagyi hails as a paradigm shift.

Read the news story or watch the interview for more.